Expert Opinion on Drug Discovery

Scope & Guideline

Fostering Collaboration for Breakthrough Discoveries

Introduction

Explore the comprehensive scope of Expert Opinion on Drug Discovery through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Expert Opinion on Drug Discovery in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1746-0441
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationEXPERT OPIN DRUG DIS / Expert. Opin. Drug Discov.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Expert Opinion on Drug Discovery' focuses on providing insights and reviews related to the methodologies and advancements in drug discovery and development. It aims to address various challenges in the field and explore new frontiers that can lead to innovative therapeutic solutions.
  1. Innovative Drug Discovery Strategies:
    The journal emphasizes novel approaches in drug discovery, including the use of artificial intelligence, machine learning, and computational methods to enhance the efficiency and accuracy of drug design.
  2. Targeted Therapeutics Development:
    It covers research aimed at developing drugs targeting specific diseases, particularly in oncology, neurology, and infectious diseases, highlighting the importance of understanding disease mechanisms.
  3. Repurposing Existing Drugs:
    The journal explores strategies for repurposing existing drugs for new therapeutic uses, especially in the context of emerging health crises such as COVID-19.
  4. Translational Research:
    There is a strong focus on bridging the gap between preclinical studies and clinical applications, emphasizing the relevance of animal models and in vitro systems in drug discovery.
  5. Emerging Technologies in Drug Discovery:
    The journal discusses advancements in technologies such as high-throughput screening, nanotechnology, and 3D cell culture models, which are pivotal for modern drug discovery.
  6. Challenges in Drug Development:
    It addresses the various challenges faced in drug development, including issues of bioavailability, drug resistance, and regulatory hurdles.
The journal has seen a significant increase in interest in several emerging themes that reflect the forefront of drug discovery research. These trends indicate a shift towards more integrated and technology-driven approaches.
  1. Artificial Intelligence and Machine Learning:
    There is a growing emphasis on the application of AI and machine learning in drug discovery, focusing on their potential to accelerate the identification and optimization of drug candidates.
  2. Complex Disease Models:
    Research on complex disease models, including polygenic and multifactorial diseases, is trending as scientists seek to better mimic human disease in preclinical settings.
  3. Biologics and RNA-based Therapeutics:
    The exploration of biologics, including monoclonal antibodies and RNA-targeted therapies, has gained traction as a promising area for innovative drug development.
  4. Personalized Medicine Approaches:
    There is an emerging focus on personalized medicine, tailoring drug discovery and development processes to individual patient profiles and genetic backgrounds.
  5. Sustainable and Ethical Drug Discovery:
    Research addressing the ethical implications and sustainability of drug discovery processes, including the use of natural products and environmentally friendly methodologies, is increasingly prominent.

Declining or Waning

While 'Expert Opinion on Drug Discovery' continues to evolve, certain themes have become less prominent in recent publications, reflecting shifts in research focus and emerging methodologies.
  1. Traditional Drug Discovery Techniques:
    There has been a noticeable decline in papers focusing solely on traditional drug discovery methods, as the field increasingly adopts advanced technologies and computational approaches.
  2. General Discussions on Drug Discovery:
    Papers that provide general overviews without a specific focus on innovative methodologies or case studies are becoming less frequent, as the journal seeks to present more targeted and impactful research.
  3. Single Target Drug Discovery:
    The trend towards polypharmacology and multi-target strategies indicates a waning interest in developing drugs that target single pathways or receptors, reflecting a more complex understanding of disease mechanisms.

Similar Journals

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Transforming Ideas into Impactful Medicinal Solutions.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0223-5234Frequency: 18 issues/year

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

Pharmaceutical Medicine

Innovating therapeutic strategies for a healthier tomorrow.
Publisher: SPRINGER INT PUBL AGISSN: 1178-2595Frequency: 6 issues/year

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

Drug Research

Advancing the Frontiers of Pharmacology
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Acta Pharmaceutica Sinica B

Unlocking New Horizons in Pharmacology and Toxicology
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

Pharmaceuticals

Leading the Charge in Open Access Pharmaceutical Research
Publisher: MDPIISSN: Frequency: 12 issues/year

Ph pharmaceuticals is a leading peer-reviewed journal published by MDPI, focused on the dynamic fields of pharmaceutical science, drug discovery, and molecular medicine. Since its inception, the journal has established itself as a vital resource for researchers and practitioners, boasting an impressive impact factor reflected in its Q1 and Q2 quartile rankings across multiple categories, including Pharmaceutical Science and Drug Discovery. As an open access journal since 2009, Pharmaceuticals promotes the dissemination of cutting-edge research and innovative findings globally, facilitating collaboration and knowledge sharing among scientists. With a robust ranking in Scopus, specifically at Rank #56 in Pharmaceutical Science and Rank #65 in Drug Discovery, the journal serves as a critical platform for advancing the field and supporting future developments in therapeutics and pharmaceuticals. Based in Switzerland, Pharmaceuticals continues to inspire a diverse readership of scholars and healthcare professionals who are dedicated to improving health outcomes through innovative research.

Drug Metabolism and Pharmacokinetics

Advancing the Frontiers of Drug Metabolism and Pharmacokinetics
Publisher: JAPANESE SOC STUDY XENOBIOTICSISSN: 1347-4367Frequency: 6 issues/year

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

TRENDS IN PHARMACOLOGICAL SCIENCES

Exploring the Future of Pharmacology and Toxicology
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

ACS Pharmacology & Translational Science

Bridging discoveries and clinical applications.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Pioneering Research for Tomorrow's Therapeutics
Publisher: MARY ANN LIEBERT, INCISSN: 1540-658XFrequency: 8 issues/year

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.

NATURE REVIEWS DRUG DISCOVERY

Advancing the frontiers of pharmaceutical innovation.
Publisher: NATURE PORTFOLIOISSN: 1474-1776Frequency: 12 issues/year

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.